TNFRSF4 and B-cell non-Hodgkin lymphoma: Stimulation of OX40/CD134 with an agonistic MoAb augments the therapeutic efficacy of anti-CD20 treatment in a B-cell lymphoma mouse model and in an NK-dependent fashion.